Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104


Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC.

Cho BC, Reinmuth N, Lee KH, Ahn MJ, Luft A, Van den Heuvel M, Dols MC, Smolin A, Vicente D, Moiseyenko V, Antonia SJ, Moulec SL, Robinet G, Natale R, Garon EB, Nakagawa K, Liu F, Thiyagarajah P, Peters S, Rizvi NA.

Ann Oncol. 2019 Apr;30 Suppl 2:ii79-ii80. doi: 10.1093/annonc/mdz094.002. No abstract available.


First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.

Amrane K, Geier M, Corre R, Léna H, Léveiller G, Gadby F, Lamy R, Bizec JL, Goarant E, Robinet G, Gouva S, Quere G, Abgral R, Schick U, Bernier C, Chouaid C, Descourt R.

Cancer Med. 2020 Feb 5. doi: 10.1002/cam4.2806. [Epub ahead of print]


Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.

Domblides C, Leroy K, Monnet I, Mazières J, Barlesi F, Gounant V, Baldacci S, Mennecier B, Toffart AC, Audigier-Valette C, Doucet L, Giroux-Leprieur E, Guisier F, Ricordel C, Molinier O, Perol M, Pichon E, Robinet G, Templement-Grangerat D, Ruppert AM, Rabbe N, Antoine M, Wislez M.

J Thorac Oncol. 2020 Jan 25. pii: S1556-0864(20)30054-X. doi: 10.1016/j.jtho.2020.01.014. [Epub ahead of print]


Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC 04-2017).

Vergnenegre A, Monnet I, Bizieux A, Bernardi M, Chiapa AM, Léna H, Chouaïd C, Robinet G.

Future Oncol. 2020 Feb;16(4):5-10. doi: 10.2217/fon-2019-0730. Epub 2020 Jan 2.


[Evolution of the costs and management of lung cancer between 2004 and 2014].

Gadby F, Descourt R, Robinet G, Quere G, Gouva S, Roge C, Couturaud F, Chouaid C.

Rev Mal Respir. 2020 Jan;37(1):1-7. doi: 10.1016/j.rmr.2019.10.010. Epub 2019 Dec 17. French.


A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.

Besse B, Barlesi F, Demedts I, Fuentes Pradera J, Robinet G, Gazzah A, Soldatenkova V, Frimodt-Moller B, Kim JS, Vansteenkiste J.

Lung Cancer. 2019 Nov;137:136-143. doi: 10.1016/j.lungcan.2019.09.002. Epub 2019 Sep 3.


Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.

Gaye E, Geier M, Bore P, Guilloïque M, Lucia F, Quéré G, Gouva S, Robinet G, Descourt R.

Lung Cancer. 2019 Jul;133:1-3. doi: 10.1016/j.lungcan.2019.04.013. Epub 2019 Apr 20.


Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.

Fouchard M, Jantzem H, Quere G, Descourt R, Robinet G, Poureau PG.

Eur J Cancer. 2019 Jul;115:107-110. doi: 10.1016/j.ejca.2019.04.022. Epub 2019 May 24. No abstract available.


Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.

Reck M, Horn L, Novello S, Barlesi F, Albert I, Juhász E, Kowalski D, Robinet G, Cadranel J, Bidoli P, Chung J, Fritsch A, Drews U, Wagner A, Govindan R.

J Thorac Oncol. 2019 Apr;14(4):701-711. doi: 10.1016/j.jtho.2019.01.010. Epub 2019 Jan 21. Erratum in: J Thorac Oncol. 2019 Aug;14(8):1484.


[Renal amyloidosis revealing a cryopyrin associated periodic syndrome].

Robinet G, Renaudineau E, Lamaison C, Cam G, Rioux-Leclercq N.

Ann Pathol. 2018 Dec;38(6):401-406. doi: 10.1016/j.annpat.2018.07.001. Epub 2018 Sep 17. French.


Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B.

ERJ Open Res. 2018 Feb 13;4(1). pii: 00058-2017. doi: 10.1183/23120541.00058-2017. eCollection 2018 Jan.


Lung Cancer in an Orthoprosthetist Using Vermiculite.

Durand-Moreau Q, Dezutter M, Quéré G, Robinet G, Le Roux PY, Loddé B, Dewitte JD.

Int J Occup Environ Med. 2017 Oct;8(4):241-243. doi: 10.15171/ijoem.2017.1133.


Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).

Auliac JB, Monnet I, Dubos-Arvis C, Chiappa AM, Baize N, Bota S, Vergnenegre A, Doubre H, Locher C, Bizieux A, Robinet G, Chouaid C.

Target Oncol. 2017 Dec;12(6):833-838. doi: 10.1007/s11523-017-0520-7.


Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.

Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenegre A, Robinet G, Auliac JB, Gervais R, Chouaid C.

Target Oncol. 2017 Oct;12(5):563-569. doi: 10.1007/s11523-017-0510-9. Review.


[A rare paratesticular tumor].

Robinet G, Rioux-Leclercq N, Fardoun T, Mathieu R, Kammerer-Jacquet SF.

Ann Pathol. 2017 Apr;37(2):206-208. doi: 10.1016/j.annpat.2016.10.003. French. No abstract available.


[Composite pheochromocytoma: A rare adrenal tumor].

Robinet G, Rioux-Leclercq N, Manunta A, Mathieu R, Tissier F, Peyronnet B, Kammerer-Jacquet SF.

Ann Pathol. 2017 Apr;37(2):158-161. doi: 10.1016/j.annpat.2016.10.001. French.


Targeted therapy for localized non-small-cell lung cancer: a review.

Paleiron N, Bylicki O, André M, Rivière E, Grassin F, Robinet G, Chouaïd C.

Onco Targets Ther. 2016 Jul 5;9:4099-104. doi: 10.2147/OTT.S104938. eCollection 2016. Review.


Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.

Quéré G, Descourt R, Robinet G, Autret S, Raguenes O, Fercot B, Alemany P, Uguen A, Férec C, Quintin-Roué I, Le Gac G.

BMC Cancer. 2016 Mar 11;16:210. doi: 10.1186/s12885-016-2249-6.


Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.

Fournel P, Vergnenégre A, Robinet G, Léna H, Gervais R, Le Caer H, Souquet PJ, Chavaillon JM, Bozonnat MC, Daurès JP, Chouaid C, Martel-Lafay I; GFPC and IFCT Team.

Eur J Cancer. 2016 Jan;52:181-7. doi: 10.1016/j.ejca.2015.10.072. Epub 2015 Dec 12.


Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).

Raynaud C, Greillier L, Mazieres J, Monnet I, Mastroianni B, Robinet G, Fraboulet G, Dixmier A, Berard H, Lamy R, Letreut J, Lena H, Oliviero G, Botta S, Vergnenegre A, Borget I, Chouaid C.

BMC Cancer. 2015 Nov 6;15:857. doi: 10.1186/s12885-015-1881-x.


Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.

Sassier M, Dugué AE, Clarisse B, Lesueur P, Avrillon V, Bizieux-Thaminy A, Auliac JB, Kaluzinski L, Tillon J, Robinet G, Le Caer H, Monnet I, Madroszyk A, Boza G, Falchero L, Fournel P, Egenod T, Toffart AC, Leiber N, Do P, Gervais R.

Lung Cancer. 2015 Aug;89(2):161-6. doi: 10.1016/j.lungcan.2015.05.005. Epub 2015 May 15.


[Systemic treatment of brain metastases from lung cancer].

Barlesi F, Spano JP, Cortot AB, Carpentier AF, Robinet G, Besse B.

Cancer Radiother. 2015 Feb;19(1):43-7. doi: 10.1016/j.canrad.2014.12.001. Epub 2015 Feb 2. Review. French.


Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.

Besse B, Le Moulec S, Mazières J, Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L, Gervais R, Robinet G, Ruppert AM, Schott R, Léna H, Clément-Duchêne C, Quantin X, Souquet PJ, Trédaniel J, Moro-Sibilot D, Pérol M, Madroszyk AC, Soria JC.

Clin Cancer Res. 2015 Apr 15;21(8):1896-903. doi: 10.1158/1078-0432.CCR-14-2082. Epub 2015 Jan 22.


Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

Chouaid C, Dujon C, Do P, Monnet I, Madroszyk A, Le Caer H, Auliac JB, Berard H, Thomas P, Lena H, Robinet G, Baize N, Bizieux-Thaminy A, Fraboulet G, Locher C, Le Treut J, Hominal S, Vergnenegre A.

Lung Cancer. 2014 Nov;86(2):170-3. doi: 10.1016/j.lungcan.2014.08.016. Epub 2014 Aug 29.


Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R; Spanish Lung Cancer Group; French Lung Cancer Group; Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing.

Ann Oncol. 2014 Nov;25(11):2147-55. doi: 10.1093/annonc/mdu389. Epub 2014 Aug 27.


Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, Blumenschein GR Jr, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC.

J Clin Oncol. 2013 Nov 10;31(32):4105-14. doi: 10.1200/JCO.2012.47.4189. Epub 2013 Oct 7.


Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study).

Vergnenègre A, Hominal S, Tchalla AE, Bérard H, Monnet I, Fraboulet G, Baize N, Audigier-Valette C, Robinet G, Oliviero G, Le Caer H, Thomas P, Gérinière L, Mastroianni B, Chouaïd C; GFPC 0804 team.

Lung Cancer. 2013 Nov;82(2):353-7. doi: 10.1016/j.lungcan.2013.07.014. Epub 2013 Aug 6.


[Evaluation of preoperative non-invasive ventilation in thoracic surgery for lung cancer: the preOVNI study GFPC 12-01].

Paleiron N, André M, Grassin F, Chouaïd C, Venissac N, Margery J, Couturaud F, Noël-Savina E, Tromeur C, Vinsonneau U, Vedrine L, Leroyer C, Nowak E, Berard H, Thomas P, Brouchet L, Bagan P, Fournel P, Mottier D, Robinet G.

Rev Mal Respir. 2013 Mar;30(3):231-7. doi: 10.1016/j.rmr.2012.10.601. Epub 2012 Dec 13. French.


Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.

Gervais R, Robinet G, Clément-Duchêne C, Denis F, El Kouri C, Martin P, Chouaki N, Bourayou N, Morère JF.

Lung Cancer. 2013 May;80(2):185-90. doi: 10.1016/j.lungcan.2013.01.008. Epub 2013 Feb 21.


Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer.

Tournoux-Facon C, Robinet G, Pinel MC, Ferre P, Tourani JM.

Am J Clin Oncol. 2012 Aug;35(4):378-85. doi: 10.1097/COC.0b013e3182143d93.


Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.


[Percutaneous implantable port-related infection and thrombosis: diagnostic and management].

Noël-Savina E, Quéré G, Gouva S, Robinet G, Descourt R.

Bull Cancer. 2011 Oct;98(9):1107-18. doi: 10.1684/bdc.2011.1403. Review. French.


Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).

Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, Bota S, Monnet I, Chajara A, Robinet G.

Ann Oncol. 2011 Nov;22(11):2466-70. doi: 10.1093/annonc/mdr003. Epub 2011 Feb 14.


Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.

Descourt R, Vergnenegre A, Barlesi F, Lena H, Fournel P, Falchero L, Berard H, Hureaux J, Le Caer H, Chavaillon JM, Geriniere L, Monnet I, Chouabe S, Robinet G; GFPC VINCR Team.

J Thorac Oncol. 2011 Feb;6(2):351-7. doi: 10.1097/JTO.0b013e318200f47e.


Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.

Vergnenegre A, Corre R, Berard H, Paillotin D, Dujon C, Robinet G, Crequit J, Bota S, Thomas P, Chouaid C; 0506 GFPC Team.

J Thorac Oncol. 2011 Jan;6(1):161-8. doi: 10.1097/JTO.0b013e318200f4c1.


[Management of non-small cell lung carcinoma following docetaxel-cisplatin. Results of an epidemiologic survey].

Breton JL, Robinet G, Dansin E, Rotarski M, Le Groumellec A, Dourthe LM, Hamid A, Ecstein-Fraisse E.

Rev Mal Respir. 2007 Nov;24(9):1099-106. French.


Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M.

Ann Oncol. 2008 Feb;19(2):362-9. Epub 2007 Oct 17.


Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis.

Chouaid C, Monnet I, Robinet G, Perol M, Fournel P, Vergnenegre A.

Curr Med Res Opin. 2007 Jul;23(7):1509-15.


An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.

LeCaer H, Barlesi F, Robinet G, Fournel P, Geriniere L, Bombaron P, Falchero L, Auliac JB, Crequit J, Chouaid C.

Lung Cancer. 2007 Jul;57(1):72-8. Epub 2007 Mar 27.


[Chemotherapy of malignant pleural mesothelioma].

Berghmans T, Bréchot JM, Robinet G, Guigay J, Morère P.

Rev Mal Respir. 2006 Sep;23(4 Pt 3):11S57-70. French. No abstract available.


Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.

Cortot AB, Gerinière L, Robinet G, Breton JL, Corre R, Falchero L, Berard H, Gimenez C, Chavaillon JM, Perol M, Bombaron P, Mercier C, Souquet PJ; Groupe Lyon-Saint-Etienne d'Oncologie Thoracique; Groupe Français de Pneumo-Cancérologie.

Ann Oncol. 2006 Sep;17(9):1412-7. Epub 2006 Jun 21.


Recurrent venous thromboembolism under anticoagulant therapy: a high risk in adenocarcinoma?

Descourt R, Le Gal G, Couturaud F, Mottier D, Bressollette L, Robinet G, Rogé C, Oger E, Leroyer C.

Thromb Haemost. 2006 May;95(5):912-3. No abstract available.


[Face presentation: retrospective study of 32 cases at term].

Ducarme G, Ceccaldi PF, Chesnoy V, Robinet G, Gabriel R.

Gynecol Obstet Fertil. 2006 May;34(5):393-6. Epub 2006 Apr 21. French.


Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).

Thomas P, Robinet G, Gouva S, Fournel P, Léna H, Le Caer H, Perol M, Berard H, Bombaron P, Vergnenegre A, Kleisbauer JP; Groupe français de pneumo-cancérologie.

Lung Cancer. 2006 Jan;51(1):105-14. Epub 2005 Nov 28.


Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study.

Fournel P, Robinet G, Thomas P, Souquet PJ, Léna H, Vergnenégre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daurés JP, Mornex F, Pérol M; Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie.

J Clin Oncol. 2005 Sep 1;23(25):5910-7. Epub 2005 Aug 8.


Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC).

Vergnenègre A, Daniel C, Léna H, Fournel P, Kleisbauer JP, Le Caer H, Letreut J, Paillotin D, Pérol M, Bouchaert E, Preux PM, Robinet G; Groupe Francais de Pneumo-Cancerologie.

Lung Cancer. 2005 Mar;47(3):395-404.


FDG PET in epithelioid hemangioendothelioma.

Rest CC, Botton E, Robinet G, Conan-Charlet V, Bizais Y, Visvikis D.

Clin Nucl Med. 2004 Dec;29(12):789-92.


[Efficacy of gefitinib (Iressa) in the treatment of an inoperable bronchioloalveolar cell carcinoma].

Bayle S, Descourt R, Gouva S, Daniel C, Robinet G.

Rev Mal Respir. 2004 Feb;21(1):153-7. French.


[Uterine rupture following hysteroscopic surgery. A case report].

Ducarme G, Maitrot F, Robinet G, Gabriel R.

Gynecol Obstet Fertil. 2004 Feb;32(2):140-2. Review. French.


[Why and how to sensibly apply the perinatal project?].

Robinet G.

Gynecol Obstet Fertil. 2003 Mar;31(3):195-6. French. No abstract available.


Supplemental Content

Loading ...
Support Center